Literature DB >> 8246699

Are healthy-years equivalents an improvement over quality-adjusted life years?

M Johannesson1, J S Pliskin, M C Weinstein.   

Abstract

The construct of the healthy-years equivalent (HYE) has been proposed as an alternative to the quality-adjusted life year (QALY) on the grounds that it avoids certain restrictive assumptions about preferences and also incorporates attitudes toward risk. The authors review the construct of the QALY, including both the commonly used risk-neutral formulation and the more general formulation that permits risk aversion (or risk preference) with respect to remaining life years. They show that the HYE adds flexibility to the risk-neutral form of the QALY by permitting the rate of tradeoff between life years and quality of life to depend on the life span, albeit at the cost of eliciting numerous additional time-tradeoff assessments. However, the claim that the HYE incorporates attitudes toward risk is incorrect, and the proposed two-stage procedure to measure HYEs is neither necessary nor sufficient to incorporate attitudes toward risk. In fact, the HYE assumes risk neutrality with respect to healthy years of life and, therefore, is less suitable for decisions under uncertainty than is the general (risk-averse) form of the QALY.

Mesh:

Year:  1993        PMID: 8246699     DOI: 10.1177/0272989X9301300403

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  4 in total

1.  Efficient use of health care resources: the interaction between improved health and reduced health related income loss.

Authors:  Michael Hoel
Journal:  Int J Health Care Finance Econ       Date:  2002-11

2.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

3.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2.

Authors:  D N Fisman; E W Hook; S J Goldie
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.